A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2012
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 01 Jul 2012 Results published in the Journal of Pathology.
- 05 Jun 2009 New trial record.